Change of 1.09% for Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI)’s short interest was reported. It was announced in March by FINRA the 1.08 million short interest on BCLI. The 1.09M previous shares are down with 1.09%. Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) has 86,400 shares average volume. It’ll cost 13 days for BCLI to restore its previous position. Brainstorm Cell Therapeutics Inc’s short interest float is 5.97%.
The stock decreased 0.53% or $0.0205 during the last trading session, hitting $3.8595.Currently Brainstorm Cell Therapeutics Inc. is uptrending after 26.80% change in last March 6, 2018. BCLI has also 52,599 shares volume. BCLI outperformed by 22.43% the S&P 500.
Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, ParkinsonÂ’s disease, and others.The firm is valued at $79.92 million. The firm holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd.Last it reported negative earnings. The Company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons.
For more Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) news posted recently go to: Globenewswire.com, Seekingalpha.com, Globenewswire.com, Nasdaq.com or Globenewswire.com. The titles are as follows: “BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences – GlobeNewswire” posted on November 07, 2018, “BrainStorm Cell Therapeutics’ (BCLI) CEO Chaim Lebovits on Q1 2018 Results – Earnings Call Transcript – Seeking Alpha” on May 14, 2018, “BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn® in Progressive Multiple Sclerosis – GlobeNewswire” with a publish date: November 19, 2018, “Health Care Sector Update for 12/17/2018: PTI, EVFM, BCLI, JNJ, PFE, MRK, ABT, AMGN – Nasdaq” and the last “BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study – GlobeNewswire” with publication date: February 22, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.